BofA Maintains Underperform Rating on GoodRx (GDRX) While Trimming PT to $2.60

Company Overview - GoodRx Holdings Inc. (NASDAQ:GDRX) provides tools for consumers to compare prices and save on prescription drug purchases in the US [4] Analyst Ratings and Price Targets - Bank of America analyst Allen Lutz lowered the price target for GoodRx from $3 to $2.60 while maintaining an Underperform rating [1] - Morgan Stanley reduced its price target for GoodRx from $5 to $4 while keeping an Equal Weight rating [2] - Barclays initiated coverage of GoodRx with an Underweight rating and a $3 price target, expressing optimism towards drug distributors but maintaining a cautious view on dental and healthcare IT sub-sectors [3] Sector Outlook - The broader drug distributor sector is viewed positively heading into 2026, with adjustments made to price targets based on recent valuation multiples across the peer group [1] - In the 2026 outlook for the Healthcare Services sector, healthcare tech and providers are seen as attractive for alpha-generation, while the managed care segment continues to face challenges [2]